Method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates
By culturing mesenchymal stem cells in microwells to form three-dimensional spheroid-type cell aggregates and separating extracellular vesicles, the method addresses the challenge of mass production and donor variation, resulting in vesicles with improved therapeutic efficacy for medical use.
Patent Information
- Application Number
- JP2023551944
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-11-05
- Filing Date
- 2021-10-26
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2041-10-26
AI Technical Summary
Current methods for producing extracellular vesicles from stem cells, particularly mesenchymal stem cells, face challenges in mass production due to the use of animal serum and limited secretion, hindering clinical application.
A method involving three-dimensional spheroid-type cell aggregates cultured in microwells with specific dimensions is used to produce extracellular vesicles, followed by separation, enabling mass production and reducing donor variation.
The method allows for the production of extracellular vesicles with enhanced therapeutic efficacy, uniform properties, and reduced donor variation, suitable for various medical applications.
Smart Images

Figure 0007591319000003 
Figure 0007591319000004 
Figure 0007591319000005
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing three-dimensional spheroid-type cell aggregates using microwells of a specific structure, thereby producing extracellular vesicles with improved therapeutic efficacy, and to extracellular vesicles produced by the method. [Background technology]
[0002] Positive clinical results have been reported for the treatment of various diseases using stem cells, especially mesenchymal stem cells (MSCs). It has been reported that most of the therapeutic efficacy of stem cell therapeutics is due to the paracrine effect of stem cells, which promotes the regeneration of surrounding skin cells and blood vessel regeneration. Extracellular vesicles (EVs) are known to be the main efficacy factor of the paracrine effect. Recently, it has been attracting attention that substances secreted by extracellular vesicles from stem cells mediate various therapeutic effects of stem cells. Extracellular vesicles are 30 to 5,000 nm in size and are classified into exosomes, microvesicles, apoptotic bodies, etc. according to size, and are called ectosomes, prostatosomes, etc. according to type and origin.
[0003] However, mass production and acquisition methods for extracellular vesicles derived from stem cells have not yet been established. Conventional methods for producing two-dimensional extracellular vesicles have been difficult to mass produce because they require xenogeneic serum or the secretion of extracellular vesicles from stem cells is limited, so a new method for mass producing extracellular vesicles suitable for clinical application is needed. Summary of the Invention [Problem to be solved by the invention]
[0004] Therefore, the present inventors have researched a method for producing three-dimensional spheroid-type cell aggregates or extracellular vesicles derived therefrom that allows for mass production and shortens the culture time. As a result, the present inventors have confirmed that when three-dimensional spheroid-type cell aggregates (3D-static-spheroids) are produced by static culture using microwells and extracellular vesicles are produced using these, extracellular vesicles with improved therapeutic efficacy are produced, thereby completing the present invention.
[0005] Therefore, the object of the present invention is to provide a method for producing three-dimensional spheroid-type cell aggregates through microwells and extracellular vesicles having improved levels of efficacy factors, and to provide extracellular vesicles produced by such a production method. [Means for solving the problem]
[0006] In order to achieve the above-mentioned object, the present invention provides a method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates, comprising: (a) a step of three-dimensionally (3D) culturing mesenchymal stem cells in a microwell having a diameter of 200 to 800 μm and a depth of 100 to 1000 μm to produce three-dimensional spheroid-type cell aggregates; and (b) a step of isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregates.
[0007] The present invention also provides extracellular vesicles produced by the above-mentioned production method.
[0008] The present invention also provides a composition for producing extracellular vesicles, comprising three-dimensional spheroid-type cell aggregates produced by three-dimensionally culturing mesenchymal stem cells in microwells having a diameter of 200 to 800 μm and a depth of 100 to 1000 μm.
[0009] The present invention also provides a method for reducing donor variation of extracellular vesicles derived from cell aggregates, comprising: (a) a step of three-dimensionally (3D) culturing stem cells in a microwell having a diameter of 200 to 800 μm and a depth of 100 to 1000 μm to produce a three-dimensional spheroid-type cell aggregate; and (b) a step of isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
[0010] The present invention also provides a method for producing extracellular vesicles derived from cell aggregates with reduced donor variation, comprising: (a) a step of three-dimensionally (3D) culturing stem cells in a microwell having a diameter of 200 to 800 μm and a depth of 100 to 1000 μm to produce a three-dimensional spheroid-type cell aggregate; and (b) a step of isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate. Effect of the Invention
[0011] By using the method for producing extracellular vesicles of the present invention, it is possible to mass-produce extracellular vesicles with enhanced efficacy. The produced extracellular vesicles contain various efficacy factors at higher levels than existing extracellular vesicles, exhibit uniform properties without donor variation, and can be used for various purposes in the medical industry. [Brief description of the drawings]
[0012] [Figure 1] FIG. 1 is a schematic diagram showing the process of producing 3D spheroid cell aggregates and isolating extracellular vesicles from them. [Figure 2-A] FIG. 1 shows an image of a microwell containing 3D-dynamic-PEG spheroid culture medium. [Figure 2-B] FIG. 1 shows an observation of a microwell containing 3D static spheroid culture medium. [Figure 2-C]FIG. 1 shows the change in aggregate area over the culture period for 3D-dynamic-PEG spheroids and 3D-static-spheroids produced using microwells. [Diagram 3] FIG. 10 compares the size distribution of 3D-static and 3D-dynamic-PEG spheroids. [Figure 4] Electron microscopy of 3D static spheroid EV morphology. [Diagram 5] FIG. 13 shows nanoparticle tracking analysis (NTA) results to confirm 3D-static-spheroid EV concentration and size distribution. [Figure 6] FIG. 13 shows the results of ELISA and Western blot to confirm the expression markers of 3D-static-spheroid EVs. [Figure 7] FIG. 11. Comparison of EV production per cell from 3D-static-spheroid EVs, 3D-dynamic-PEG spheroid EVs and 2D-EVs. [Figure 8] FIG. 13. Highly expressed miRNAs and proteins in 3D-static-spheroid EVs compared to 2D-EVs. [Figure 9] FIG. 13. Highly expressed miRNAs and proteins in 3D-static-spheroid EVs compared to 3D-dynamic-PEG spheroid EVs. [Figure 10] This figure shows the results of confirming donor variation and differences in angiogenesis- and nerve regeneration-related miRNA expression levels among 2D-cultured WJ-MSCs, 3D-cultured WJ-MSCs, 2D-EVs, and 3D-static spheroid EVs. [Figure 11] This figure shows changes in mRNA expression after treating 3D-static-spheroid EVs or 2D-EVs with vascular endothelial cells (HUVECs) or neural stem cells (pNSCs (primitive neural stem cells)). [Figure 12] This figure shows the change in infarct area depending on the concentration of 3D-static-spheroid EV treatment in a rat stroke model. [Figure 13] A ladder walking test was performed in a stroke rat model to measure neurological behavior recovery according to 3D-static-spheroid EV treatment concentration. [Figure 14] Confocal microscopy of cells treated with CFSE-labeled 3D-static-spheroid EVs. [Figure 15] This figure confirms that miR-27a-3p is delivered to cells by CFSE-labeled 3D static spheroid EVs. BEST MODE FOR CARRYING OUT THEINVENTION
[0013] The present invention provides a method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates, comprising: (a) three-dimensionally (3D) culturing stem cells in microwells having a diameter of 200 to 800 μm and a depth of 100 to 1000 μm to produce three-dimensional spheroid-type cell aggregates; and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregates.
[0014] In the present invention, the cells can be used without limitation as long as they can be isolated from extracellular vesicles, and may be cells isolated from objects of natural organisms. The cells may be derived from any type of animal or plant, including humans and non-human mammals, and may be various types of immune cells, tumor cells, or stem cells. Preferably, the stem cells may be mesenchymal stem cells, pluripotent stem cells, induced pluripotent stem cells, or embryonic stem cells.
[0015] In the present invention, the three-dimensional culture means culturing in a three-dimensional configuration in a test tube. Unlike two-dimensional culture, three-dimensional culture allows cells to grow in any direction in vitro, creating an environment more similar to the cellular environment in vivo.
[0016] In the present invention, the three-dimensional culture in step (a) may be performed by any three-dimensional cell culture technique known in the technical field to which the present invention belongs, and may be, for example, cell culture using microwell array culture, porous microparticle culture, hanging drop culture, low attachment plate culture, membrane-based cell-detachment culture, thermal lifting culture, centrifugation culture, semisolid medium culture, etc. Preferably, the three-dimensional culture may be dynamic culture or static culture, and more preferably, static culture. In the present invention, when the three-dimensional culture in step (a) is static culture, no device required for shaking culture is required, which makes the culture easier and enables mass culture in a GMP (Good manufacturing practices, a standard for manufacturing and quality control of pharmaceuticals and quasi-drugs) manufacturing facility.
[0017] In the present invention, the three-dimensional culture in step (a) may be for 1 to 10 days, and preferably for 2 to 4 days. In particular, when the culture in step (a) in the present invention is for 2 to 4 days, the survival rate of cells present in the three-dimensional spheroid-type cell aggregate is maintained at a high level, and the culture time is relatively short compared to the existing process for producing three-dimensional spheroid-type cell aggregates, so that three-dimensional spheroid-type cell aggregates and extracellular vesicles derived therefrom can be rapidly produced.
[0018] In the present invention, the three-dimensional culture in step (a) may be performed by dispensing mesenchymal stem cells into microwells at a density of 100 to 1000 cells / well and culturing them, and preferably, by dispensing them at a density of 200 to 600 cells / well and culturing them.
[0019] In the present invention, the step of separating extracellular vesicles in step (b) may be performed by physical or chemical separation. The physical separation may be extrusion of a sample containing cells or cell aggregates, and the chemical separation may be treatment with a chemical substance capable of separating extracellular vesicles from cells or cell aggregates. For example, the separation step of the present invention may be performed using a method selected from the group consisting of ultrasonic decomposition, cell lysis, homogenization, freezing-thawing, electroporation, chemical treatment, mechanical decomposition, and treatment with a physical stimulus that applies a force externally to cells, and may be a physicochemical method in which ions are separated through binding with a specific biomarker by an ion or affinity chromatography method, or an immunoaffinity EV capture or exosome purification reagent, ExoCAS-2 reagent or method in which cells are broken down using a polymer and a reagent, and only extracellular vesicles are bound and separated, and preferably, separation may be performed by a tangential flow filtration (TFF) method, but is not limited thereto.
[0020] In the present invention, MicroRNA is a type of RNA and is named by adding "mir" in front and "-" and a number after it. In this case, the number often indicates the order of naming. For example, mir-123 was named before mir-156 and is expected to have been discovered earlier. "mir-" indicates pre-microRNA, and "miR" with capital letters means mature microRNA. MicroRNAs with almost the same sequence except for one or two sequences are named with lower case letters. For example, miR-121a and miR-121b are generated by their respective precursors mir-121a and mir-121b, and their sequences are very similar. Pre-microRNAs that are the same but located at different sites on the genome are named with "-" and a number after them. For example, the pre-microRNAs mir-121-1 and mir-121-2 are the same mature microRNA (miR-121), but are located at different sites on the genome. The name of the microRNA is written in the beginning according to the species. For example, hsa-miR-123 is a human (Homo sapiens) microRNA, and oar-miR-123 is a sheep (Ovis aries) microRNA. "v" stands for viral (miRNA encoded by a viral genome), and "d" stands for Drosophila microRNA. When two mature microRNAs are derived from different arms (3'arm or 5'arm) of the same pre-microRNA, "-3p" or "-5p" is added to the end. (Previously, the above categories were written as "s" (sense) and "as" (antisense).) miR-142-3p is derived from the 3'arm, and miR-142-5p is derived from the 5'arm. MicroRNA nomenclature is generally based on the criteria above, although exceptions exist.
[0021] In the present invention, the extracellular vesicles may have a higher expression of various substances exhibiting therapeutic efficacy compared to known extracellular vesicles, and the various substances exhibiting therapeutic efficacy may be substances exhibiting effects on angiogenesis, neurogenesis, cell protection, immune regulation, rejuvenation, vascular / BBB permeability stabilization, anti-cancer effects, or targeting. Preferably, the extracellular vesicles may express at a higher level one or more selected from the group consisting of miR-146a, miR-27a, miR-132, miR-184, miR-210, and miR-301b, and / or at a higher level one or more selected from the group consisting of integrin 1 / 2, and VEGF / R2 (Vascular Endothelial Growth Factor Receptor 2) than extracellular vesicles derived from spheroid-type cell aggregates obtained by three-dimensional dynamic culture of mesenchymal stem cells, or may express at a higher level one or more selected from the group consisting of miR-27a, miR-146a, miR-146b, integrin 1 / 2, and at a higher level one or more selected from the group consisting of VEGF / R2 (Vascular Endothelial Growth Factor Receptor 2) than extracellular vesicles derived from two-dimensionally cultured mesenchymal stem cells. More preferably, the extracellular vesicles of the present invention may express miR-146a, miR-27a, miR-132, miR-184, miR-210 and miR-301b; and / or integrin 1 / 2, and VEGF / R2 at higher levels than extracellular vesicles derived from spheroid-type cell aggregates formed by three-dimensional dynamic culture of mesenchymal stem cells, or may express miR-27a, miR-146a and miR-146b; and / or integrin 1 / 2, and VEGF / R2 at higher levels than extracellular vesicles derived from two-dimensionally cultured mesenchymal stem cells.
[0022] In addition, the extracellular vesicles may be mixed into cells and internalized when treated with cells, and may be mixed into cells and internalized, thereby effectively delivering clinically significant substances to cells and allowing them to be highly expressed in the cells.
[0023] In the present invention, "extracellular vesicles derived from spheroid-type cell aggregates obtained by three-dimensional dynamic culture of mesenchymal stem cells" may include, without limitation, extracellular vesicles separated from spheroid-type cell aggregates obtained by three-dimensional dynamic culture of mesenchymal stem cells, and may preferably be extracellular vesicles disclosed in a Korean registered patent (application number 10-2016-0053026, method for producing extracellular vesicles derived from stem cells).
[0024] In the present invention, "extracellular vesicles derived from two-dimensionally cultured mesenchymal stem cells" may include, without limitation, extracellular vesicles obtained by culturing stem cells according to a conventional two-dimensional culture method and isolating them using a conventional method for isolating extracellular vesicles. In the examples of the present invention, the conventional two-dimensional culture method was carried out by washing stem cells cultured for 3 days in a cell stack with PBS, exchanging the medium for serum-free medium, and culturing for another 2 days, and evaluating the results.
[0025] In the present invention, the three-dimensional spheroid cell aggregate may have an average diameter of 65 to 133 μm, preferably 99.20±11.47 μm, and more preferably, as a result of measuring the size distribution of 154 of the three-dimensional spheroid cell aggregates, the average diameter may be 99.20 μm and the coefficient of variation (CV) may be 11.6%. The (dimensional) spheroid cell aggregate of the present invention may have a higher kurtosis of the size distribution than "spheroid cell aggregates obtained by three-dimensional dynamic culture of mesenchymal stem cells". Thus, the size of the three-dimensional spheroid cell aggregate may be smaller than "spheroid cell aggregates obtained by three-dimensional dynamic culture of mesenchymal stem cells" and have a relatively uniform size distribution.
[0026] In the present invention, the microwells may be formed of any of the following compounds: TMSPMA (3-(trimethoxysilyl)propylmethacrylate), HEA (hydroxyethyl acrylate), GMA (glycidyl methacrylate), EGDMA (diethyleneglycol dimethacrylate), THFA (tetrahydrofurfuryl acrylate), HMAA (hydroxymethyl acrylamide), PEA (phenyl epoxyacrylate), HOFHA (6-hydroxy-2,2,3,3,4,4,5,5-octafluoro (6-Hydroxy-2,2,3,3,4,4,5,5-octafluoro), EOPT (Polyethoxylated(4)pentaerythritoltetraacrylate), HPA (Hydroxypropyl acrylate), BMA (Butylmethacrlate), PETIA (Pentaerythritol triacrylate), HDDA (Hexan diol diacrylate), EGPEA (Ethyleneglycol phenyletheracrylate), BM (Benzylmethacrylate), HPPA (Hydroxyphenoxypropyl acrylate), BHPEA (2-(4-Benzoyl-3-hydroxyphenoxy)ethylacrylate), HEMA (Hydroxyethyl The substrate may be coated with any one selected from the group consisting of HPMA (N-(2-hydroxypropyl)methacrylamide) and MPC (2-methacryloyloxyethyl phosphorylcholine polymer), and preferably coated with MPC (2-methacryloyloxyethyl phosphorylcholine polymer), but is not limited thereto.
[0027] The microwell of the present invention may have a structure with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm, and the mesenchymal stem cells cultured in the structure may maintain a high level of viability even after the culture time has elapsed.
[0028] When extracellular vesicles are produced by the "method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates" of the present invention, in addition to the advantages of static culture, extracellular vesicles having improved therapeutic efficacy can be rapidly and efficiently mass-produced. In particular, the method for producing extracellular vesicles of the present invention is characterized by being suitable for GMP application.
[0029] The present invention also provides extracellular vesicles produced by the above-mentioned production method.
[0030] In the present invention, the extracellular vesicles may be those which express therapeutically effective substances at a higher level than known extracellular vesicles. Preferably, the extracellular vesicles may be those which express at a higher level one or more selected from the group consisting of miR-146a, miR-27a, miR-132, miR-184, miR-210 and miR-301b, and / or at least one selected from the group consisting of integrin 1 / 2 and VEGF / R2 (Vascular Endothelial Growth Factor Receptor 2) than extracellular vesicles derived from spheroid-type cell aggregates obtained by three-dimensional dynamic culture of mesenchymal stem cells, and may be those which express at a higher level one or more selected from the group consisting of miR-27a, miR-146a, miR-146b, integrin 1 / 2 and at least one selected from the group consisting of VEGF / R2 (Vascular Endothelial Growth Factor Receptor 2) than extracellular vesicles derived from two-dimensionally cultured mesenchymal stem cells. More preferably, the extracellular vesicles of the present invention may express miR-146a, miR-27a, miR-132, miR-184, miR-210 and miR-301b; and / or integrin 1 / 2, and VEGF / R2 at higher levels than extracellular vesicles derived from spheroid-type cell aggregates obtained by three-dimensional dynamic culture of mesenchymal stem cells, or may express miR-27a, miR-146a and miR-146b; and / or integrin 1 / 2, and VEGF / R2 at higher levels than extracellular vesicles derived from two-dimensionally cultured mesenchymal stem cells.
[0031] In the present invention, the extracellular vesicles may have an average particle diameter of 172.5 to 192.5 nm and a mode diameter of 96.1 to 116.1 nm.
[0032] Furthermore, extracellular vesicles derived from three-dimensional spheroid-type cell aggregates produced by the production method of the present invention can be characterized in particular by reduced donor variation.
[0033] In the present invention, the extracellular vesicles may reduce the area of cerebral infarction and induce neurological behavior recovery when administered to an individual who has suffered from cerebral infarction. Preferably, the extracellular vesicles may exhibit the effect of reducing the area of cerebral infarction and induce neurological behavior recovery in a smaller amount than extracellular vesicles produced by existing known methods.
[0034] The present invention also provides a composition for producing extracellular vesicles containing three-dimensional spheroid-type cell aggregates produced by three-dimensionally culturing mesenchymal stem cells in microwells having a diameter of 200 to 800 μm and a depth of 100 to 1000 μm.
[0035] In the present invention, the composition may contain, without limitation, any component necessary for producing extracellular vesicles.
[0036] The present invention also provides a method for reducing donor variation of extracellular vesicles derived from cell aggregates, comprising: (a) a step of three-dimensionally (3D) culturing stem cells in a microwell having a diameter of 200 to 800 μm and a depth of 100 to 1000 μm to produce a three-dimensional spheroid-type cell aggregate; and (b) a step of isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
[0037] The present invention also provides a method for producing extracellular vesicles derived from cell aggregates with reduced donor variation, comprising: (a) a step of three-dimensionally (3D) culturing stem cells in a microwell having a diameter of 200 to 800 μm and a depth of 100 to 1000 μm to produce three-dimensional spheroid-type cell aggregates; and (b) a step of isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregates.
[0038] According to the method of the present invention, the difference in the composition of miRNA between extracellular vesicles derived from the obtained cell aggregates due to the donor can be reduced, and extracellular vesicles having uniform properties can be produced. More specifically, in the present invention, the reduction in donor variation refers to reducing the difference in the composition of miRNA produced by the donor, and showing a consistent miRNA profile regardless of the donor. More preferably, compared to 2D-EV, it may be that the miRNAs that can show angiogenic or neural regeneration effects, such as miR-27a-3p, miR-146a-5p, miR-210, and miR-132, are more uniformly contained, or that the miRNAs related to angiogenesis and neural regeneration, such as miR-199a, miR-125b, miR-26a, let-7, miR-125a, miR-181b, and miR-92a, are expressed to a uniform degree regardless of the origin of each donor.
[0039] Duplicate content will be omitted in consideration of the complexity of this specification, and terms not otherwise specified in this specification have the meanings commonly used in the technical field to which this invention belongs.
[0040] The present invention will be described in detail below with reference to examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0041] Western blot Cells and extracellular vesicles were dissolved in radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.5% triton X-100, 1% Na-deoxycholate, 0.1% sodium dodecyl sulfate (SDS), and protease inhibitors). A total of 20 μg of protein was separated by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The nitrocellulose membrane was then incubated overnight at 4°C with primary antibodies against histone H2A.Z, histone H3, lamin A / C, flotillin-1 (1:1,000, Cell signaling technology, Beverly, MA, USA), or calreticulin (1:1,000, ThermoFisher Scientific, Inc., Rockford, IL, USA). After washing with Tris-buffered saline-Tween 20, the nitrocellulose membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (1:1,000, anti-rabbit, Cell Signaling Technology, Beverly, MA, USA) for 2 h. Proteins were detected using a chemiluminescent substrate from ThermoFisher Scientific, Inc. (Waltham, MA, USA). Labeled proteins were visualized through X-ray film (Agfa, Mortsel, Belgium).
[0042] ELISA ELISA was performed with commercial kits according to the individual manufacturer's manual. The following ELISA kits were used: gentamicin (5111GEN, EuroProxima, Arnhem, Nederland), bovine albumin (8100, Alpha Diagnostic, San Antonio, TX, USA), Hsp70 (Abcam, Cambridge, UK), CD63, CD9 and CD81 (System Biosciences, Palo Alto, CA, USA), histone H2A.Z. (Mybiosource, San Diego, CA, USA), calreticulin (Mybiosource) and cytochrome C (ThermoFisher Scientific, Inc.). All kits contain standard proteins; therefore, the amount of protein and extracellular vesicles is determined based on the standard curve of each kit.
[0043] qPCR Trizol in EV TM RNA was extracted using a kit according to the manufacturer's instructions, and RNA was quantified using a nanodrop. RNA was made into cDNA through a reverse transcription (RT) process, and Real Time PCR was performed using Taqman probes appropriate for each miRNA and mRNA according to the manufacturer's manual.
[0044] EV labeling and uptake by cells Purified EVs were stained with CFSE (5-(and-6)-Carboxyfluorescein Diacetate, Succinimidyl Ester) labeling dye (c-1157, Invitrogen) according to the manufacturer's guidelines. Excess dye was removed by ultracentrifugation at 100.000g for 1 hour. Labeled EVs (0.4 μg / ml) were treated with human NSC cell line (ReNcells) and cultured for 24 hours. After treatment, cells were washed twice with PBS and stained using a standard immunocytochemistry protocol. Cells were incubated with mouse anti-SMA (1:100, Sigma Aldrich) antibody at 4°C overnight. Then, cells were washed with PBS and incubated with secondary antibody DyLight-labeled anti-mouse IgG (1:200, 594 nm, Abcam) antibody. Vectashield with 1.5 μg / mL 4'-6'diamidino-2-phenylindole (DAPI) (Vector Laboratories) TM After nuclear staining with , cells were imaged using a confocal microscope (LSM 700, Carl Zeiss, Germany).
[0045] Example 1. Isolation of extracellular vesicles through three-dimensional culture of mesenchymal stem cells 1.1 Preparation of mesenchymal stem cells Human umbilical cord-derived mesenchymal stem cells (WJ-MSCs) at passage 5 (hereafter referred to as passage 5, Samsung Medical Center, Seoul, Korea) were purchased and incubated at 37°C, 5% CO 2 The cells were cultured in an incubator. The growth medium used was α-modified eagle's medium (α-MEM, GIBCO, NY, USA) containing 10% fetal bovine serum (FBS) (GIBCO, NY, USA) and 50 μg / mL gentamicin (GIBCO, NY, USA). WJ-MSCs at passage 6 were used to generate 3D spheroid-type cell aggregates.
[0046] 1.2 Preparation of 3D spheroid-type cell aggregate culture medium The WJ-MSCs prepared in Example 1.1 were washed with PBS and treated with trypsin (TrypLE TM Express, GIBCO, NY, USA) processed by CO 2 The cells were incubated in an incubator for 5 minutes. After that, new serum-free medium was added, trypsin was neutralized, the cells were collected, and a cell pellet was obtained using a centrifuge. Next, new serum-free medium was added, a cell suspension was prepared, and the cells were counted. After cell counting, 60 ml of the cell suspension was evenly dispensed to a microarray containing microwells coated with MPC (2-Methacryloyloxyethyl Phosphorylcholine Polymer) with a diameter and depth of 500 μm × 200 μm, at a density of 400 cells / well, and the cells were incubated in a static state for a total of 4 days at 37°C in CO 2 The cells were cultured in an incubator to produce a 3D spheroid-type cell aggregate culture medium (hereinafter referred to as 3D-static-spheroid culture medium).
[0047] 1.3 Isolation of extracellular vesicles from 3D spheroid-type cell aggregates The 3D-static spheroid culture medium prepared in Example 1.2 was collected, centrifuged at 2,500 g for 10 minutes to remove cells and debris, and filtered with a 0.22 μm syringe filter. The 3D-static spheroid culture medium was then filtered through a 300 kDa hollow fiber membrane (Pall, NY, USA) using a tangential flow filtration (TFF) system to remove proteins, and the extracellular vesicles were primarily separated and purified again with physiological saline to obtain highly pure 3D-static spheroid-derived extracellular vesicles (hereinafter referred to as 3D-static spheroid EVs) of the present invention.
[0048] The processes of Examples 1.1 to 1.3 are illustrated in FIG.
[0049] Example 2. Analysis of the properties of 3D spheroid-type cell aggregates The characteristics of the 3D spheroid-type cell aggregates (hereinafter referred to as 3D-static-spheroids) present in the 3D-static-spheroid culture solution prepared in Example 1.2 were analyzed. The 3D-static-spheroid culture solution prepared in Example 1.2 was used as the experimental group, and the 3D mesenchymal stem cell spheroid-type cell aggregates (hereinafter referred to as 3D-dynamic-PEG spheroids) culture solution prepared by culturing mesenchymal stem cells for 5 days according to the dynamic 3D cell culture method disclosed in the registered patent (Application No. 10-2016-0053026, Method for Producing Extracellular Vesicles Derived from Stem Cells) was used as the comparative group. The microwells containing each culture solution were observed under an optical microscope, as shown in A and B of FIG. 2, and the area change of the spheroid-type cell aggregates after culture compared to the initial culture is shown in C of FIG. 2.
[0050] As shown in Figure 2, the area of the 3D-static spheroids (experimental group) was compared with that of the 3D-dynamic-PEG spheroids (comparison group), and the 3D-static spheroids maintained an area of about 70% of that of the spheroids at the initial stage of culture. However, the 3D-dynamic-PEG spheroids showed cell debris, and the area was reduced to about 50% of that of the spheroids at the initial stage of culture. The difference in the area reduction rate between the 3D-static spheroids and the 3D-dynamic-PEG spheroids was statistically significant at p≦0.5 (p=0.019753).
[0051] Example 3. Size analysis of 3D spheroid cell aggregates The size distribution of the 3D-static spheroids prepared in Example 1.2 and the 3D-dynamic-PEG spheroids prepared in Example 3 was measured, and the coefficient of variation, skewness, and kurtosis were analyzed based on the measured size distribution data.
[0052] Skewness is a parameter that indicates the direction and degree of inclination of the distribution from the trend of the median, and the closer it is to 1, the more the distribution has a long tail to the right, and the closer it is to -1, the more the distribution has a long tail to the left. The skewness of a normal distribution is 0.
[0053] Kurtosis is a parameter that indicates the sharpness of a data distribution. A positive value indicates that a relatively large number of data points are concentrated in the center, and a negative value indicates that a relatively small number of data points are concentrated in the center. For a normal distribution, kurtosis is 0.
[0054] The measured size distribution data is shown in FIG. 3, and the analysis results are shown in Table 1.
[0055] [Table 1]
[0056] As shown in Figure 3 and Table 1, the average size of the 3D-static spheroids was 99.20 μm with a coefficient of variation (CV) of 11.6%. In contrast, the average size of the 3D-dynamic PEG spheroids was 148.66 μm with a coefficient of variation (CV) of 14.1%. To compare the measured coefficients of variation, Feltz and Miller's (1996) asymmetric test was performed with a p-value of 0.01765604, and Krishnamoorthy and Lee's (2014) modified signed-likelihood ratio test was performed with a p-value of 0.01853969. Therefore, it was confirmed that the size distributions of the 3D-static spheroids and the 3D-dynamic PEG spheroids were statistically significantly different in both tests. Comparing the size distribution of 3D-static spheroids and 3D-dynamic-PEG spheroids, it was confirmed that the kurtosis value of the size distribution of the 3D-static spheroids is relatively large, and that the size distribution of the 3D-static spheroids of the present invention shows a tendency to be concentrated at the median. From these results, it was confirmed that when 3D spheroids are produced by the method for producing 3D-static spheroids of the present invention, 3D spheroids with a relatively uniform size can be produced.
[0057] Example 4. Analysis of the morphology of extracellular vesicles derived from 3D spheroid-type cell aggregates To observe the morphology of the 3D-static spheroid EVs isolated in Example 1.3, images were taken using a transmission electron microscopy (TEM). Specifically, the 3D-static spheroid EVs were isolated by dissolving 1% OsO in 0.1 M phosphate buffer (PB). 4 The EM grid was adsorbed with formvar side down onto the droplet of extracellular vesicles for 1 min. It was then blotted with filter paper and reacted with 2% uranyl acetate for 15 s. Excess uranyl acetate was removed, and the EM grid was observed using a TEM (JEM-1011, JEOL, Japan). The observed images are shown in Figure 4.
[0058] As shown in Figure 4, the 3D-static-spheroid EVs were confirmed to have a round shape, which is a typical morphology of extracellular vesicles.
[0059] Example 5. Analysis of concentration and size of extracellular vesicles derived from 3D spheroid-type cell aggregates To confirm the concentration and size distribution of the 3D-static-spheroid EVs isolated in Example 1.3, nanoparticle tracking analysis (NTA) was performed using a NanoSight NS300 (Malvern, Worcestershire, UK). For optimal analysis, the 3D-static-spheroid EVs were pre-diluted in vesicle-free phosphate buffered saline (PBS). The average size and concentration (particle / mL) were calculated by integrating three recordings, and the results are shown in Figure 5.
[0060] As shown in Figure 5, the mean particle diameter of the 3D-static-spheroid EVs was confirmed to be 182.5 nm, and the mode diameter was 106.1 nm.
[0061] Example 6. Expression marker analysis of extracellular vesicles derived from 3D spheroid-type cell aggregates An experiment was conducted to confirm the expression markers of the 3D-static spheroid EVs isolated in Example 1.3. Cell lysate and secretome were used as controls. The cell lysate was prepared by washing the 3D-static spheroids with PBS, treating them with trypsin, recovering the cells, and obtaining a cell pellet from the recovered cells using a centrifuge. The secretome was prepared by obtaining the cell pellet, isolating EVs from the culture medium, which is the supernatant, through the process of Example 1.3, and obtaining the remaining culture secretome. Marker analysis was performed by quantifying the positive markers CD9, CD63, CD81, and HSP70 specific to extracellular vesicles using ELISA, and quantifying the specific contaminating protein markers calreticulin, histone H2A.Z, cytochrome C, albumin, and antibiotics. In addition, we quantified the specific contaminating protein markers of extracellular vesicles, histone H2A.Z, histone H3, lamin A / C, and calreticulin, and quantified the positive marker for extracellular vesicles, flotillin-1, using Western blot. The results of the ELISA analysis and the Western blot are shown in Figure 6.
[0062] As shown in Figure 6, 3D-static-spheroid EVs expressed all of the extracellular vesicle-specific positive markers CD9, CD63, CD81, and HSP70, and showed little expression of the contaminating protein markers calreticulin, histone H2A.Z, histone H3, cytochrome C, albumin (BSA, bovine serum albumin), lamin A / C, and antibiotics, which are highly expressed in cell lysates and secretomes. In particular, it was confirmed that flotillin-1, an extracellular vesicle-positive marker that is expressed very low in cell lysates, was relatively highly expressed in 3D-static-spheroid EVs.
[0063] Example 7. Analysis of extracellular vesicle production from 3D spheroid-type cell aggregates An experiment was conducted to compare the production amounts of 3D-static-spheroid EVs, which are extracellular vesicles produced by the production method of Example 1, extracellular vesicles isolated from the 3D-dynamic-PEG spheroids of Example 2 (3D-dynamic-PEG spheroid EVs), and extracellular vesicles isolated from stem cells cultured by a conventional 2D culture method (2D-EVs). 2D-EVs were prepared by the following process. Stem cells cultured for 3 days in a cell stack were washed with PBS, replaced with serum-free medium, and cultured for another 2 days. The culture medium was collected, and cellular debris was successively removed using centrifugation and a 0.2 μm filter. Then, the culture medium was passed through a hollow fiber membrane using a TFF system to remove proteins, and EVs were primarily separated and purified again with physiological saline to obtain highly pure 2D-EVs. The production amounts per cell derived from the prepared 3D-static-spheroid EVs, 3D-dynamic-PEG spheroid EVs, and 2D-EVs were compared, and the results are shown in Table 2 and Figure 7.
[0064] [Table 2]
[0065] Example 8. Analysis of expressed microRNA (miRNA) in extracellular vesicles derived from 3D spheroid-type cell aggregates 8.1 Identification of miRNAs with increased expression in 3D-static-spheroid EVs To confirm the differences in the characteristics of 3D-static-spheroid EVs, which are extracellular vesicles produced by the manufacturing method of Example 1, 3D-dynamic-PEG spheroid EVs, which are extracellular vesicles isolated from the 3D-dynamic-PEG spheroids of Example 2, and 2D-EVs produced in Example 7, the expression of miRNAs and protein were measured via qPCR. The miRNAs and proteins that were more highly expressed in 3D-static-spheroid EVs compared to 2D-EVs are shown in Figure 8, and the miRNAs and proteins that were more highly expressed in 3D-static-spheroid EVs compared to 3D-dynamic-PEG spheroid EVs are shown in Figure 9.
[0066] As shown in Figure 8, compared to 2D-EVs, 3D-static-spheroid EVs were confirmed to highly express miR-27a, miR-146b, and miR-146a, which are miRNAs that are effective in angiogenesis / neurogenesis and immune regulation, and to highly express integrin 1 / 2 and VEGF / R2 (Vascular endothelial growth factor / R2), which are proteins that are effective in angiogenesis / neurogenesis.
[0067] As shown in Figure 9, compared to the 3D-dynamic-PEG spheroid EVs, the 3D-static-spheroid EVs were confirmed to highly express miR-146a, an miRNA effective in angiogenesis / neurogenesis and immune regulation, miR-27a, miR-132, miR-184, and miR-210, which are miRNAs effective in angiogenesis / neurogenesis, and miR-301b, which has anti-tumor efficacy, as well as highly express integrin 1 / 2 and VEGF / R2, which are proteins effective in angiogenesis / neurogenesis, compared to the 3D-dynamic-PEG spheroid EVs.
[0068] From these results, it was confirmed that the 3D-static spheroid EVs, which are extracellular vesicles produced by the manufacturing method of Example 1, are new extracellular vesicles with different miRNA and protein expression compared to 2D-EVs or 3D-dynamic-PEG spheroid EVs, and in particular, that they highly express miRNAs related to angiogenesis / neurogenesis, immune regulation, rejuvenation or anti-tumor, making them clinically useful extracellular vesicles.
[0069] 8.2 Analysis of miRNA expression differences by donor Stem cell therapeutics are known to have a problem of donor variation, whereby components are different depending on the donor. An experiment was conducted to confirm whether the 3D-static-spheroid EV of the present invention shows a more consistent miRNA profile without the problem of donor variation. Samples from each donor were provided and used from Samsung Medical Center (Seoul, Korea). The miRNA profiles of the 2D-cultured WJ-MSCs and 3D-cultured WJ-MSCs of Example 1.1 and the 3D-static-spheroid EVs, which are extracellular vesicles, prepared by the method of Example 1, were compared for each donor. miRNA was profiled by small RNA sequencing, and the results are shown in FIG. 10.
[0070] As shown in Figure 10, 2D-cultured WJ-MSCs and 2D-EVs showed large differences in the composition of miRNAs produced by donors, whereas 3D-cultured WJ-MSCs and 3D-static-spheroid EVs showed reduced differences due to donors. In particular, 3D-static-spheroid EVs showed a consistent miRNA profile without differences due to donors, and in particular, compared to 2D-EVs, it was confirmed that miRNAs that can show angiogenic or neural regenerative effects, such as miR-27a-3p (1.5-fold), miR-146a-5p (2.3-fold), miR-210 (2.6-fold), and miR-132 (2.6-fold), were more uniformly contained. In addition, it was confirmed that other miRNAs related to angiogenesis and nerve regeneration, such as miR-199a, miR-125b, miR-26a, let-7, miR-125a, miR-181b, and miR-92a, also showed uniform levels of expression between donors.
[0071] These results indicate that 3D-static-spheroid EVs can reduce the difference in therapeutic active ingredients depending on the donor and show better therapeutic efficacy.
[0072] Example 9. Analysis of mRNA expression when cells are treated with extracellular vesicles derived from 3D spheroid-type cell aggregates 3D-static-spheroid EVs, which are extracellular vesicles prepared by the manufacturing method of Example 1, and 2D-EVs, which are extracellular vesicles isolated from stem cells cultured using a conventional 2D culture method, were treated with vascular endothelial cells (HUVECs) or neural stem cells (pNSCs (primitive neural stem cells)), and changes in mRNA expression were confirmed using qPCR. The qPCR results are shown in Figure 11.
[0073] As shown in Figure 11, compared to cells treated with 2D-EV, vascular endothelial cells (HUVECs) treated with 3D-static spheroid EVs showed increased expression of VEGF (Vascular endothelial growth factor), Hif-1a (Hypoxia-inducible factor 1-alpha), and FGF (Fibroblast growth factor), and pNSCs treated with 3D-static spheroid EVs showed increased expression of VEGF, BDNF (Brain-derived neurotrophic factor), FGF, NGF (Nerve growth factor), and HGF (Hepatocyte growth factor). In particular, compared to the control group, pNSCs treated with 2D-EVs showed decreased expression of NGF and HGF, while pNSCs treated with 3D-static spheroid EVs showed increased expression of NGF and HGF, confirming that 3D-static spheroid EVs and 2D-EVs show different effects even in normal conditions.
[0074] VEGF, BDNF, NGF, HGF and Hif-1a are angiogenesis / neurogenesis-related proteins, and FGF is a factor that corresponds to a protein that regulates biological functions related to cell proliferation, survival and differentiation. It was confirmed that 3D-static-spheroid EVs, which have a relatively high effect of increasing the expression of VEGF, BDNF, NGF, HGF, Hif-1a and FGF, are excellent extracellular vesicles for clinical application.
[0075] Example 10. Effect of 3D-static-spheroid EVs on stroke rat model 10.1 Preparation of the stroke rat model To prepare a stroke rat model, transient middle cerebral artery occlusion (tMCAo) was induced using the intraluminal vascular occlusion method. Specifically, male Sprague-Dawley rats (8 weeks old, 270–300 g) were used. The rats were inhaled with 1.5% isoflurane, 70% N 2 O and 30% O 2 Rats were anesthetized with 500 ng / mL acetone (500 ng / mL) and maintained at 37.0–37.5°C with a heating pad during surgery. A 4-0 surgical monofilament nylon suture with a round tip was advanced from the left common carotid artery into the lumen of the internal carotid artery until the origin of the middle cerebral artery was occluded. The suture was withdrawn until the tip occluded the lumen of the common carotid artery, and middle cerebral artery occlusion (tMCAo) was performed, followed by reperfusion 90 min later. Rats that developed hemorrhagic transformation or subarachnoid hemorrhage caused by rupture of the intracranial artery and rats that did not show observable neurological deficits after tMCAo were excluded from the analysis.
[0076] 10.2 Verification of the effect of 3D-static-spheroid EVs in reducing cerebral infarction area in a stroke rat model The stroke rat model prepared in Example 10.1 was used as the treatment for the 3D-static-spheroid EVs at a concentration of 3 × 10 8 , 30×10 8EVs / rat were treated differently, and 4 weeks after treatment, MRI was taken to measure changes in the area where infarcts occurred. As a control group, a PBS-treated group was used, and the changes in the measured infarct areas are shown in Figure 12.
[0077] As shown in Figure 12, compared with the control group, 8 It was confirmed that the infarct area was significantly reduced in all experimental groups treated with EVs / rat or higher concentrations.
[0078] These results suggest that extracellular vesicles derived from spheroid-type cell aggregates produced by the previously known 3D method were 30 × 10 8 Considering that treatment with a concentration of EVs / rat or higher showed a significant reduction in the area of cerebral infarction, it was confirmed that 3D-static-spheroid EVs are effective in reducing the area of cerebral infarction even in small amounts.
[0079] 10.3 Neurological behavioral recovery of 3D-static-spheroid EVs in a stroke rat model The stroke rat model prepared in Example 10.1 was used as the treatment for the 3D-static-spheroid EVs at a concentration of 3 × 10 8 , 30×10 8 The 3D-static-spheroid EVs were treated with different EVs / rats and a ladder walking test was performed to verify the neurological behavioral recovery ability of the EVs. The PBS-treated group was used as a control group, and the 3×10 8 Human umbilical cord-derived mesenchymal stem cells were used at a cell / rat concentration.
[0080] The specific ladder walking test method is as follows. Before and after middle cerebral artery occlusion (tMCAo), the ladder walking test was performed on days 4, 7, 14, and 28 by a single observer who was unaware of the experimental conditions. The ladder apparatus for the experiment consisted of a metal horizontal ladder across which the animal walked and a transparent side wall. The number of foot faults and the total number of steps were measured, and the percentage of foot faults was calculated. The calculated percentage of foot faults is shown in Figure 13.
[0081] As shown in FIG. 13, the ladder walking test was performed 4 days after middle cerebral artery occlusion, and the results showed that the 3×10 8 , 30×10 8 We confirmed that the rate of foot faults was significantly reduced only in the 3D-static-spheroid EV-treated group compared to the control group at a concentration of EVs / rat of 30 × 10 8 It was confirmed that the 3D-static-spheroid EV treatment group with a concentration of EVs / rat reduced the percentage of foot faults in all sections.
[0082] These results confirmed that 3D-static-spheroid EVs rapidly induce neurological behavior recovery compared to mesenchymal stem cells. These results suggest that extracellular vesicles derived from spheroid-type cell aggregates produced by the previously known 3D method were 30×10 8 Compared to the fact that a significant degree of neurological behavior recovery was observed when treated with EVs / rat at a concentration of 100 or more, the results show that the 3D-static-spheroid EVs of the present invention can effectively induce neurological behavior recovery even in small amounts.
[0083] Example 11. Evaluation of cell contamination and miRNA delivery capacity of 3D-static-spheroid EVs 11.1 Assessment of cell-contaminating potential of 3D-static-spheroid EVs To evaluate the cell contamination ability of 3D-static-spheroid EVs, CFSE-labeled 3D-static-spheroid EVs were treated into human NSC cell line (ReNcells), cultured for 24 hours, and confirmed by confocal microscopy (LSM700, Carl Zeiss, Germany), which is shown in Figure 14. As shown in Figure 14, it was confirmed that when 3D-static-spheroid EVs were treated with cells, they were mixed into the cells and internalized.
[0084] 11.2 Evaluation of miRNA expression by 3D-static-spheroid EV treatment In Example 11.1, the expression of miR-27a-3p was measured using RT-qPCR in human NSC cell lines (ReNcells) treated with CFSE-labeled 3D-static-spheroid EVs. As a control group, human NSC cell lines (ReNcells) not treated with labeled 3D-static-spheroid EVs were used, and the results are shown in Figure 15.
[0085] As shown in FIG. 15, it was confirmed that the expression of miR-27a-3p was significantly increased in cells treated with 3D-static-spheroid EVs compared to the control group.
[0086] Through this, it was confirmed that when cells are treated with 3D-static-spheroid EVs, clinically significant substances highly expressed in 3D-static-spheroid EVs, such as miR-27a-3p, are effectively delivered to the cells.
[0087] As described above, the specific parts of the present invention have been described in detail. It is obvious to those skilled in the art that such specific techniques are merely preferred embodiments and do not limit the scope of the present invention. Therefore, it is believed that the true scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. (a) dispensing stem cells into microwells having a diameter of 200-800 μm and a depth of 100-1000 μm at a density of 200-600 cells / well, and three-dimensionally (3D) statically culturing the stem cells in the microwells to produce three-dimensional spheroid-type cell aggregates; and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregates.
2. 2. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, wherein the stem cells are at least one selected from the group consisting of mesenchymal stem cells, pluripotent stem cells, induced pluripotent stem cells, and embryonic stem cells.
3. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, wherein the three-dimensional culture in step (a) is performed for 1 to 10 days.
4. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, wherein the step of separating the extracellular vesicles in step (b) is performed by physical or chemical separation.
5. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, further comprising a step of filtering the extracellular vesicles after centrifuging the cells prior to the step of isolating the extracellular vesicles in step (b).
6. 2. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, wherein the step of isolating the extracellular vesicles in step (b) is performed by a tangential flow filtration (TFF) method.
7. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, wherein the extracellular vesicles highly express one or more types selected from the group consisting of miR-146a, miR-27a, miR-132, miR-184, miR-210 and miR-301b compared to extracellular vesicles derived from spheroid-type cell aggregates obtained by three-dimensional dynamic culture of mesenchymal stem cells.
8. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, wherein the extracellular vesicles highly express one or more species selected from the group consisting of miR-27a, miR-146a, and miR-146b compared to extracellular vesicles derived from two-dimensionally cultured mesenchymal stem cells.
9. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, wherein the extracellular vesicles highly express one or more selected from the group consisting of integrin 1 / 2 and VEGF / R2 (Vascular Endothelial Growth Factor Receptor 2) compared to extracellular vesicles derived from spheroid-type cell aggregates obtained by three-dimensional dynamic culture of mesenchymal stem cells.
10. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, wherein the extracellular vesicles highly express one or more selected from the group consisting of integrin 1 / 2 and VEGF / R2 (Vascular Endothelial Growth Factor Receptor 2) compared to extracellular vesicles derived from two-dimensionally cultured mesenchymal stem cells.
11. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, wherein the three-dimensional spheroid-type cell aggregates have an average diameter of 65 to 133 μm.
12. The microwells may be provided with TMSPMA (3-(trimethoxysilyl)propyl methacrylate), HEA (hydroxyethyl acrylate), GMA (glycidyl methacrylate), EGDMA (diethylene glycol dimethacrylate), THFA (tetrahydrofurfuryl acrylate), HMAA (hydroxymethyl acrylamide), PEA (phenyl epoxyacrylate), HOFHA (6-hydroxy-2,2,3,3,4,4,5,5-octafluoro), EOPT (polyethoxylated (4) pentaerythritol tetraacrylate), HPA (hydroxypropyl acrylate), BMA (butyl methacrylate), PETIA (pentaerythritol triacrylate), HDDA (hexane diol diacrylate), EGPEA (ethylene glycol phenyl ether acrylate), BM (benzyl methacrylate), HPPA (hydroxyphenoxypropyl The method for producing extracellular vesicles derived from the three-dimensional spheroid cell aggregate according to claim 1, wherein the extracellular vesicles are coated with any one selected from the group consisting of BHPEA (2-(4-benzoyl-3-hydroxyphenoxy)ethyl acrylate), HEMA (hydroxyethyl methacrylate), HPMA (N-(2-hydroxypropyl) methacrylamide) and MPC (2-methacryloyloxyethyl phosphorylcholine polymer).
13. The method for producing extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to claim 1, characterized in that the extracellular vesicles derived from three-dimensional spheroid-type cell aggregates have reduced donor variation.
14. An extracellular vesicle derived from a three-dimensional spheroid-type cell aggregate produced by the production method according to any one of claims 1 to 13.
15. The extracellular vesicles derived from the three-dimensional spheroid-type cell aggregates according to claim 14, characterized in that the donor variation is reduced.
16. A composition for producing extracellular vesicles containing three-dimensional spheroid-type cell aggregates produced by dispensing mesenchymal stem cells at a density of 200 to 600 cells / well into microwells having a diameter of 200 to 800 μm and a depth of 100 to 1000 μm, and three-dimensionally (3D) statically culturing the mesenchymal stem cells in the microwells.
17. (a) dispensing stem cells into microwells having a diameter of 200-800 μm and a depth of 100-1000 μm at a density of 200-600 cells / well, and three-dimensionally (3D) statically culturing the stem cells in the microwells to produce three-dimensional spheroid-type cell aggregates; and (b) isolating extracellular vesicles from the three-dimensional spheroid cell aggregates;
18. (a) dispensing stem cells into microwells having a diameter of 200-800 μm and a depth of 100-1000 μm at a density of 200-600 cells / well, and three-dimensionally (3D) statically culturing the stem cells in the microwells to produce three-dimensional spheroid-type cell aggregates; and (b) isolating extracellular vesicles from the three-dimensional spheroid cell aggregates. A method for producing extracellular vesicles derived from cell aggregates having reduced donor variation.
Citation Information
Patent Citations
Composition for preventing or treating pulmonary fibrosis, comprising exosomes extracted from adipose-derived stem cells as an active ingredient
JP2019527702A
Method of preparing stem cell-derived extracellular vesicles
KR101991038B1
A method for regulation of angiogenesis cytokine in stem cell-derived extracellular vesicles by using mechanical stiffness of hydrogel
KR1020200113838A
Method for producing stem cell-derived extracellular vesicle
US20190144830A1
